N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock
2007

NT-proBNP as a Prognostic Factor in Cancer Patients with Septic Shock

Sample size: 51 publication Evidence: moderate

Author Information

Author(s): Mokart Djamel, Sannini Antoine, Brun Jean-Paul, Faucher Marion, Blaise Didier, Blache Jean-Louis, Faucher Catherine

Primary Institution: Paoli-Calmette Institute

Hypothesis

Can N-terminal pro-brain natriuretic peptide (NT-proBNP) levels predict ICU mortality in cancer patients with septic shock?

Conclusion

NT-proBNP levels can help identify high-risk cancer patients with septic shock within the first 24 hours of diagnosis.

Supporting Evidence

  • The ICU mortality rate was 51%, indicating a significant risk for cancer patients with septic shock.
  • NT-proBNP levels were significantly higher in patients with cardiac dysfunction compared to those without.
  • An NT-proBNP level above 6,624 pg/ml predicted ICU mortality with high sensitivity and specificity.

Takeaway

Doctors can use a blood test called NT-proBNP to see if cancer patients with a serious infection are likely to survive their hospital stay.

Methodology

A prospective observational study was conducted over one year with 51 cancer patients diagnosed with septic shock.

Limitations

The study had a small sample size and lacked comprehensive hemodynamic data due to reliance on echocardiography.

Participant Demographics

The study included 51 patients, with a median age of 56 years, consisting of 32 men (63%) and 19 women (37%).

Statistical Information

P-Value

0.022

Confidence Interval

1.004 to 1.32

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/cc5721

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication